Cefuroxime Sodium

Impetigo, Maxillary Sinusitis, Bacterial Meningitis + 17 more

Treatment

2 FDA approvals

20 Active Studies for Cefuroxime Sodium

What is Cefuroxime Sodium

Cefuroxime

The Generic name of this drug

Treatment Summary

Cefepime is a type of antibiotic used to treat infections caused by both gram-positive and gram-negative bacteria. It is particularly effective for infections caused by gonorrhea and certain strains of haemophilus. Cefepime is also resistant to the enzyme beta-lactamase, which some bacteria use to defend against antibiotics.

Zinacef

is the brand name

image of different drug pills on a surface

Cefuroxime Sodium Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zinacef

Cefuroxime

1989

163

Approved as Treatment by the FDA

Cefuroxime, commonly known as Zinacef, is approved by the FDA for 2 uses such as Bacterial Infections and Urinary Tract Infection (UTI) .

Bacterial Infections

Urinary Tract Infection (UTI)

Effectiveness

How Cefuroxime Sodium Affects Patients

Cefuroxime is an antibiotic that belongs to the cephalosporin family. It works by blocking bacteria from producing proteins that are essential for them to survive and reproduce, which kills the bacteria and stops the infection. Cefuroxime is effective against a variety of bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Borrelia burgdorferi. The drug form of

How Cefuroxime Sodium works in the body

Cefuroxime is a type of antibiotic that works by binding to proteins located inside bacterial cells. Doing so blocks the synthesis of the cell wall, causing the bacteria to burst. It also likely interferes with an inhibitor that keeps the bacteria from self-destructing.

When to interrupt dosage

The advocated measure of Cefuroxime Sodium is contingent upon the determined issue, including Gonorrhea, Urinary Tract Infection (UTI) and Bone and Joint Infections. The amount of dosage fluctuates, as per the technique of administration (e.g. Intravenous or Tablet, film coated) noted in the table beneath.

Condition

Dosage

Administration

Maxillary Sinusitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

prophylaxis of infection in minor cuts, scrapes, or burns

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Animal bite

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Bacterial Infections

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

mild Streptococcal pharyngitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

moderate Streptococcal tonsillitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Urinary Tract Infections

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Osteomyelitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Bronchitis, Chronic

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Otitis Media

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Tonsillitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Septicemia

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Urinary Tract Infection (UTI)

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Impetigo

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Bacterial Meningitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

moderate Streptococcal pharyngitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Operative Surgery

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Gonorrhea

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Lyme Disease

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Bronchitis

, 1500.0 mg, 750.0 mg, 7500.0 mg, 750.0 mg/mL, 90.0 mg/mL, 500.0 mg, 250.0 mg, 150.0 mg/mL, 7.5 mg/mL, 15.0 mg/mL, 250.0 mg/mL, 125.0 mg, 125.0 mg/mL, 75000.0 mg, 225000.0 mg, 95.0 mg/mL, 75.0 mg/mL

, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Suspension, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous, Powder, Powder - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Granule, for suspension - Oral, Granule, for suspension, Powder, for solution - Oral, Suspension - Oral

Warnings

Cefuroxime Sodium has one contraindication, and it should not be administered if you are encountering any of the conditions in the following table.

Cefuroxime Sodium Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Cefuroxime Sodium.

Common Cefuroxime Sodium Drug Interactions

Drug Name

Risk Level

Description

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Neomycin.

Tenofovir

Major

Cefuroxime may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Cefuroxime may increase the nephrotoxic activities of Tenofovir alafenamide.

Tenofovir disoproxil

Major

Cefuroxime may increase the nephrotoxic activities of Tenofovir disoproxil.

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cefuroxime.

Cefuroxime Sodium Toxicity & Overdose Risk

Allergic reactions such as rashes, sneezing, throat dryness, eye irritation, or severe allergic shock may occur with cephalosporin overdose. It can also lead to brain irritation and seizures.

image of a doctor in a lab doing drug, clinical research

Cefuroxime Sodium Novel Uses: Which Conditions Have a Clinical Trial Featuring Cefuroxime Sodium?

146 active trials are currently assessing the utility of Cefuroxime Sodium for the management of moderate Streptococcal pharyngitis, Bacterial Infections and Animal bites.

Condition

Clinical Trials

Trial Phases

Gonorrhea

0 Actively Recruiting

Operative Surgery

70 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 2, Early Phase 1

moderate Streptococcal pharyngitis

0 Actively Recruiting

prophylaxis of infection in minor cuts, scrapes, or burns

0 Actively Recruiting

Maxillary Sinusitis

0 Actively Recruiting

Septicemia

1 Actively Recruiting

Not Applicable

Tonsillitis

0 Actively Recruiting

Bronchitis, Chronic

0 Actively Recruiting

moderate Streptococcal tonsillitis

0 Actively Recruiting

Bronchitis

2 Actively Recruiting

Not Applicable

Lyme Disease

2 Actively Recruiting

Phase 1, Phase 2, Not Applicable

Bacterial Meningitis

0 Actively Recruiting

Animal bite

0 Actively Recruiting

Otitis Media

0 Actively Recruiting

Impetigo

0 Actively Recruiting

Bacterial Infections

0 Actively Recruiting

mild Streptococcal pharyngitis

0 Actively Recruiting

Urinary Tract Infections

9 Actively Recruiting

Not Applicable, Phase 4, Early Phase 1

Osteomyelitis

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Cefuroxime Sodium Reviews: What are patients saying about Cefuroxime Sodium?

5

Patient Review

7/25/2018

Cefuroxime Sodium for infection caused by bacteria

IV Cefuroxime was prescribed to me for tick borne infections and it worked very well. I did experience some soreness in my throat and swollen glands, but that was from the bacteria dying off. Otherwise, no negative side effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cefuroxime sodium

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is cefuroxime sodium used for?

"Cefuroxime is used to injected to treat various infections, examples include pneumonia, meningitis, gonorrhea, and skin, blood, bone, joint, and urinary infections caused by bacteria."

Answered by AI

Is cefuroxime a strong antibiotic?

"Do cefuroxime and amoxicillin work for the same infections? Both drugs are commonly used to treat similar types of infections; however, there are some types of infection where one may be better."

Answered by AI

Does cefuroxime contain sodium?

"This is equivalent to 4% of the recommended maximum daily dietary intake of sodium for an adult.

Each vial of Cefuroxime Injection 750mg contains 40.6mg of sodium, which is equivalent to 2% of the recommended maximum daily dietary intake of sodium for an adult. Each vial of Cefuroxime Injection 1.5g contains 81.3mg of sodium, which is equivalent to 4% of the recommended maximum daily dietary intake of sodium for an adult."

Answered by AI

What drug class is cefuroxime sodium?

"Cefuroxime belongs to a class of antibiotics called cephalosporins. These drugs work by preventing the growth of bacteria."

Answered by AI

Clinical Trials for Cefuroxime Sodium

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Medstar National Rehabilitation Hospital in Washington D.C., United States.

Lactobacillus Crispatus for Urinary Tract Infection

18+
All Sexes
Washington D.C., United States

The goal of this clinical trial is to determine whether Lactobacillus crispatus strains isolated from the lower urinary tracts of adult women can be used as an antibiotic-sparing treatment for urinary symptoms and urinary tract infection (UTI) among adults with neurogenic lower urinary tract dysfunction (NLUTD). The main question\[s\] it aims to answer are: 1. To identify soluble bactericidal compounds produced by urinary isolates of L. crispatus that kill uropathogenic E. coli (UPEC). 2. To determine if intravesical instillation of L. crispatus is safe and well tolerated in adults with NLUTD due to SCI who use intermittent catheterization (IC). If there is a comparison group: Researchers will compare L. Crispatus to standard care saline to see if there is a difference in urinary symptoms and urinary microbiome. Participants will be asked to complete daily symptom surveys, complete 2 bladder instillations, and collect, freeze, and return 14 urine samples.

Phase < 1
Recruiting

Medstar National Rehabilitation Hospital

Suzanne Groah, MD

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD

Have you considered Cefuroxime Sodium clinical trials?

We made a collection of clinical trials featuring Cefuroxime Sodium, we think they might fit your search criteria.
Go to Trials
Image of UPMC Shadyside Hospital in Pittsburgh, United States.

Bright Green Light Therapy for Postoperative Pain

18+
All Sexes
Pittsburgh, PA

This is an unblinded, parallel group randomized controlled trial to evaluate bright green light as an adjunct therapy after surgery at UPMC Shadyside. The primary outcome measure will be pain intensity with secondary outcome measures including opioid requirements, sleep quality, mood, and overall post-operative recovery. Specific aims/hypotheses for this study are as follows: Aim 1: To assess bright green light therapy's potential as a complementary post-operative analgesic strategy in patients recovering from surgery Hypothesis 1: Participants exposed to bright green light, in comparison to dim white (ambient) light, will have improved postoperative pain scores and lower opioid use. Aim 2: To examine the impact of bright green light therapy on patient-centered measures of post-operative recovery that may be related to improved circadian function. Hypothesis 2: Participants exposed to bright green light, in comparison to dim white (ambient) light, will have improved quality of post-operative recovery, enhanced sleep, and reduced anxiety and depression.

Waitlist Available
Has No Placebo

UPMC Shadyside Hospital

Rebecca Kotcher, MD

Image of Walter Reed National Military Medical Center in Bethesda, United States.

Corticosteroid Injections for Osteoarthritis

18+
All Sexes
Bethesda, MD

The goal of this clinical trial is to find out which type of steroid medicine, when added to a standard pain-control injection during total knee replacement surgery, works best at reducing pain, limiting opioid use, and improving recovery in adults undergoing surgery for severe knee arthritis or injury. The main questions it aims to answer are: Does adding a steroid to the injection improve pain control and reduce opioid use after surgery? Is the newer extended-release steroid (Zilretta) more effective and safer-especially for patients with diabetes-than the traditional steroid (methylprednisolone)? Researchers will compare: Standard pain-control injection alone Standard injection plus methylprednisolone Standard injection plus Zilretta to see which option provides better pain relief, less opioid use, and improved knee function. (Patients with diabetes or prediabetes will only be in the standard injection or Zilretta groups so researchers can study whether Zilretta is safer for blood sugar control.) Participants will: Be randomly assigned to one of the study groups during their total knee replacement surgery Receive the assigned pain-control injection around the knee joint Be followed after surgery to measure: Pain levels Opioid pain medication use Knee movement (range of motion) Whether another procedure (such as manipulation under anesthesia) is needed if the knee becomes too stiff Patient-reported outcome surveys about pain and function

Phase 2 & 3
Waitlist Available

Walter Reed National Military Medical Center

John P Cody, MD

Have you considered Cefuroxime Sodium clinical trials?

We made a collection of clinical trials featuring Cefuroxime Sodium, we think they might fit your search criteria.
Go to Trials
Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA

At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.

Waitlist Available
Has No Placebo

UPMC Magee-Womens Hospital

Anna Binstock, MD

Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits

Phase 4
Waitlist Available

University of California, San Francisco

Alexandra Bicki, MD

Have you considered Cefuroxime Sodium clinical trials?

We made a collection of clinical trials featuring Cefuroxime Sodium, we think they might fit your search criteria.
Go to Trials